 STONY BROOK, N.Y.--BUSINESS WIRE--- APDN COVID19--Applied DNA Sciences, Inc. NASDAQ: APDN the Company, a leader in Polymerase Chain Reaction PCR-based DNA manufacturing, today announced consolidated financial results for the three and six months ended March 31, 2021. We are pleased to deliver a strong fiscal second quarter with year-over-year revenue growth of 384, capping an impressive first half of the fiscal year distinguished by demand for our COVID-19 diagnostics and surveillance testing offer 